Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of written informed consent.~* Over 18 years of age.~* Mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, at screening (Study Day 0).~* Previous participation in Clinical ZS-002 or ZS-003 protocol(s). However, subjects cannot be enrolled in this study until at least 30 days have elapsed from their last dose in study ZS-003.~* Ability to have repeated blood draws or effective venous catheterization.~* Women of childbearing potential must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at screening.~Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of child-bearing potential.~Exclusion Criteria:~* Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed blood specimen, severe leukocytosis or thrombocytosis.~* Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for hyperammonemia within the last 7 days.~* Subjects treated with resins (such as Sevelamer acetate), calcium acetate, calcium carbonate, or lanthanum carbonate, within the last 7 days.~* Subjects treated with Sodium Polystyrene Sulfonate (SPS; e.g. Kayexalate®) or ZS (microporous, fractionated, protonated zirconium silicate) within the last 30 days.~* Subjects with a life expectancy of less than 3 months.~* Subjects who are HIV positive.~* Subjects who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol.~* Women who are pregnant, lactating, or planning to become pregnant.~* Subjects with diabetic ketoacidosis.~* Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.~* Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.~* Previous treatment with SPS.~* Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.~* Subjects with cardiac arrhythmias that require immediate treatment.~* Subjects on insulin where a stable dose has not yet been established.\*~* Subjects on dialysis. \* Subjects on stable insulin or insulin analogues can be enrolled. Subjects who have been on the same insulin dose and regimen for \> 14 days are considered stable. Whenever possible, all blood draws collected prior to meals should be collected prior to insulin/insulin analogue treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium Polystyrene Sulfonate (Type: ACTIVE_COMPARATOR): Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
- Silicified microcrystalline cellulose (Type: PLACEBO_COMPARATOR): Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues